{"id":"pramlintide-insulin","safety":{"commonSideEffects":[{"rate":"~30–50%","effect":"Hypoglycemia"},{"rate":"~20–30%","effect":"Nausea"},{"rate":"~5–10%","effect":"Vomiting"},{"rate":"~10–15%","effect":"Anorexia"},{"rate":"~5–10%","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pramlintide is an amylin analog that acts as a neuroendocrine regulator to delay gastric emptying, suppress postprandial glucagon secretion, and promote satiety. When combined with insulin, it provides complementary glucose-lowering effects: insulin drives glucose uptake and storage, while pramlintide reduces the rate of nutrient absorption and hepatic glucose production after meals. This combination addresses multiple pathophysiologic defects in diabetes.","oneSentence":"Pramlintide slows gastric emptying and suppresses glucagon secretion, while insulin lowers blood glucose, together improving postprandial glucose control in diabetes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:02:04.863Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus (in combination with insulin)"},{"name":"Type 2 diabetes mellitus (in combination with insulin)"}]},"trialDetails":[{"nctId":"NCT06422325","phase":"NA","title":"Two Way Crossover Closed Loop Study Insulin vs Insulin and Pramlintide","status":"COMPLETED","sponsor":"Oregon Health and Science University","startDate":"2024-07-12","conditions":"Type 1 Diabetes","enrollment":33},{"nctId":"NCT06046417","phase":"PHASE2, PHASE3","title":"A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2023-11-30","conditions":"type1diabetes, Diabetes Mellitus, Type 1","enrollment":30},{"nctId":"NCT04074317","phase":"PHASE2","title":"Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D","status":"COMPLETED","sponsor":"Xeris Pharmaceuticals","startDate":"2019-08-22","conditions":"Diabetes Mellitus, Type 1, Insulin-dependent Diabetes Mellitus","enrollment":18},{"nctId":"NCT05199714","phase":"NA","title":"A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2022-02-21","conditions":"Type 1 Diabetes","enrollment":12},{"nctId":"NCT04243629","phase":"NA","title":"Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System in Adults With Type 1 Diabetes","status":"UNKNOWN","sponsor":"McGill University","startDate":"2021-11-12","conditions":"Diabetes Mellitus, Type 1, Type 1 Diabetes, Postprandial Hyperglycemia","enrollment":26},{"nctId":"NCT04163874","phase":"NA","title":"Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas","status":"COMPLETED","sponsor":"McGill University","startDate":"2020-02-14","conditions":"Type 1 Diabetes, Type 1 Diabetes Mellitus, Hyperglycemia, Postprandial","enrollment":36},{"nctId":"NCT03547427","phase":"NA","title":"Glucagon Counterregulation in Type 1 Diabetes","status":"TERMINATED","sponsor":"University of Virginia","startDate":"2018-05-20","conditions":"Type 1 Diabetes Mellitus","enrollment":13},{"nctId":"NCT04972175","phase":"PHASE1","title":"Safety and Efficacy of BC LisPram","status":"UNKNOWN","sponsor":"Michael Tsoukas","startDate":"2021-07-28","conditions":"Type1 Diabetes Mellitus","enrollment":16},{"nctId":"NCT03800875","phase":"PHASE2","title":"Insulin-plus-pramlintide Closed-loop Strategy to Regulate Glucose Levels Without Carbohydrate Counting","status":"COMPLETED","sponsor":"McGill University","startDate":"2019-02-08","conditions":"Diabetes Mellitus, Type 1","enrollment":24},{"nctId":"NCT03993366","phase":"NA","title":"Pramlintide and Fiasp Closed-Loop With a Simple Meal Announcement","status":"COMPLETED","sponsor":"McGill University","startDate":"2019-03-01","conditions":"Type 1 Diabetes Mellitus","enrollment":8},{"nctId":"NCT03981627","phase":"PHASE1, PHASE2","title":"A Trial to Assess Safety and Efficacy of ADO09 Versus Insulin Aspart in Subjects With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Adocia","startDate":"2019-06-06","conditions":"Type 1 Diabetes Mellitus","enrollment":44},{"nctId":"NCT00790699","phase":"NA","title":"Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port","status":"TERMINATED","sponsor":"Texas Diabetes & Endocrinology, P.A.","startDate":"2009-08","conditions":"Type 1 Diabetes, Type 2 Diabetes","enrollment":31},{"nctId":"NCT02814123","phase":"PHASE2","title":"Effect of Basal-Bolus Closed-Loop Co-Administration of Insulin and Pramlintide on Improving the Glycemic Control in Type 1 Diabetes","status":"COMPLETED","sponsor":"McGill University","startDate":"2017-01-13","conditions":"Diabetes Mellitus, Type 1","enrollment":28},{"nctId":"NCT03916640","phase":"PHASE1","title":"A Trial to Assess a Co-formulation of an Insulin Analog and Pramlintide in Subjects With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Adocia","startDate":"2019-01-04","conditions":"Type 1 Diabetes Mellitus","enrollment":24},{"nctId":"NCT03512236","phase":"PHASE1","title":"A Trial to Investigate Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BioChaperone® Pramlintide Insulin in Patients With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Adocia","startDate":"2018-04-25","conditions":"Type 1 Diabetes Mellitus","enrollment":24},{"nctId":"NCT00505882","phase":"PHASE4","title":"Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes","status":"WITHDRAWN","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-07","conditions":"Type 1 Diabetes","enrollment":""},{"nctId":"NCT02500979","phase":"PHASE1","title":"Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-08-17","conditions":"Type 1 Diabetes Mellitus","enrollment":34},{"nctId":"NCT01165944","phase":"PHASE1, PHASE2","title":"Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes Mellitus","status":"WITHDRAWN","sponsor":"University of Colorado, Denver","startDate":"2009-08","conditions":"Diabetes Mellitus","enrollment":""},{"nctId":"NCT00442767","phase":"PHASE4","title":"Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2007-02","conditions":"Type 1 Diabetes Mellitus","enrollment":8},{"nctId":"NCT01269047","phase":"PHASE4","title":"Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2009-08","conditions":"Type 1 Diabetes","enrollment":37},{"nctId":"NCT01269008","phase":"PHASE1","title":"Closed Loop System With Pramlintide Versus Exenatide","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2010-12","conditions":"Type 1 Diabetes","enrollment":13},{"nctId":"NCT00291772","phase":"PHASE4","title":"Continuous Subcutaneous Infusion of Pramlintide and Insulin","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2006-01","conditions":"Type 1 Diabetes","enrollment":13},{"nctId":"NCT00042601","phase":"PHASE2","title":"Evaluation of the Effect of Pramlintide on Satiety and Food Intake","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-07","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":51},{"nctId":"NCT00042458","phase":"PHASE3","title":"Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-04","conditions":"Diabetes Mellitus, Type 1","enrollment":296},{"nctId":"NCT00842075","phase":"NA","title":"Pramlintide in Adolescents With Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2006-12","conditions":"Type 1 Diabetes","enrollment":10},{"nctId":"NCT00108004","phase":"PHASE3","title":"Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2003-04","conditions":"Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus","enrollment":400},{"nctId":"NCT00467649","phase":"PHASE4","title":"A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-05","conditions":"Type 2 Diabetes Mellitus","enrollment":112},{"nctId":"NCT00240253","phase":"PHASE4","title":"A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-10","conditions":"Type 2 Diabetes Mellitus","enrollment":200},{"nctId":"NCT00229658","phase":"","title":"An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-09","conditions":"Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus","enrollment":1297},{"nctId":"NCT01708044","phase":"PHASE1","title":"Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2012-11","conditions":"Type 1 Diabetes","enrollment":32},{"nctId":"NCT01434862","phase":"NA","title":"Pramlintide Combined With Model Predictive Control Algorithm","status":"TERMINATED","sponsor":"University of Virginia","startDate":"2011-02","conditions":"Type 1 Diabetes Mellitus","enrollment":2},{"nctId":"NCT01839370","phase":"NA","title":"Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2013-07","conditions":"Diabetes Mellitus, Type 1","enrollment":9},{"nctId":"NCT00502138","phase":"PHASE4","title":"A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"University Diabetes & Endocrine Consultants","startDate":"2007-07","conditions":"IDDM","enrollment":12},{"nctId":"NCT00460304","phase":"NA","title":"The Effect of Pramlintide on Meal Time Insulin Bolus","status":"COMPLETED","sponsor":"Diabetes Care Center","startDate":"2007-09","conditions":"Type 1 Diabetes","enrollment":12}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pramlintide Acetate"],"phase":"marketed","status":"active","brandName":"Pramlintide + Insulin","genericName":"Pramlintide + Insulin","companyName":"Montefiore Medical Center","companyId":"montefiore-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pramlintide slows gastric emptying and suppresses glucagon secretion, while insulin lowers blood glucose, together improving postprandial glucose control in diabetes. Used for Type 1 diabetes mellitus (in combination with insulin), Type 2 diabetes mellitus (in combination with insulin).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}